Search This Blog

Friday, July 26, 2013

U.S. FDA Acknowledges Receipt of Resubmission of the New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes | BMS Newsroom

U.S. FDA Acknowledges Receipt of Resubmission of the New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes | BMS Newsroom

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.